GEOVAX LABS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
GEOVAX LABS, INC. (GOVX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-09-17
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.00.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.00.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 S-1 · filed 2026-09-17 | |||
| 2025-12-31 | $0.00 S-1 · filed 2026-09-17 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-09 | |||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-12 | |||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-01 | |||
| 2012-12-31 | $0.00 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |